NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Microsatellite Stable, MGMT Silenced Metastatic Colorectal Cancer

NCT03832621 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

135

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG: Temozolomide
DRUG: Nivolumab
DRUG: Ipilimumab

Sponsor

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano